Form 4: Monte Rosa COO Reports Equity Grants, Tax-Related Stock Sale

Monte Rosa Therapeutics' Chief Operating Officer, Jennifer Champoux, reported the grant of 35,000 restricted stock units and 158,000 stock options, alongside a tax-related sale of 2,629 common shares.

Summary

• Jennifer Champoux, Chief Operating Officer of Monte Rosa Therapeutics, Inc. (GLUE), reported recent equity transactions.
• On January 2, 2026, Ms. Champoux was granted 35,000 Restricted Stock Units (RSUs) under the Issuer's 2021 Stock Option and Incentive Plan.
• Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement.
• The RSUs will vest 25% on January 2, 2027, with the remainder vesting in three equal annual installments thereafter, subject to continued service.
• Also on January 2, 2026, Ms. Champoux was granted 158,000 stock options with an exercise price of $15.31 and an expiration date of January 1, 2036.
• These stock options will vest 25% on January 2, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to continued service.
• On January 5, 2026, Ms. Champoux sold 2,629 shares of common stock at a weighted average price of $15.17 per share.
• These shares were sold in multiple transactions at prices ranging from $15.17 to $15.43.
• The sale was mandatory to cover tax withholding obligations related to the vesting of restricted stock units and was not at the discretion of the reporting person.
• Following these transactions, Ms. Champoux beneficially owns 62,371 shares of common stock and 158,000 stock options.

Sentiment

Score: 5

Explanation: The filing reports routine insider equity transactions, including grants and a tax-related sale, which are neutral in sentiment. It does not contain information that would significantly alter the company's fundamental outlook.

Positives

• Grant of 35,000 Restricted Stock Units (RSUs) to the Chief Operating Officer, aligning her interests with shareholders.
• Grant of 158,000 stock options with an exercise price of $15.31, providing long-term incentive for performance and retention.

Negatives

• Sale of 2,629 shares of common stock, reducing direct beneficial ownership, although this was for tax withholding purposes and not discretionary.

Risks

• Vesting of both Restricted Stock Units and stock options is subject to the reporting person's continued service with the company.
• The value of the granted equity awards is subject to the future market price of Monte Rosa Therapeutics' common stock.

Future Outlook

The equity grants, including Restricted Stock Units and stock options, are structured with multi-year vesting schedules extending through January 2, 2027, and beyond, contingent on the Chief Operating Officer's continued service, indicating a long-term incentive and retention strategy.

Industry Context

This Form 4 filing details routine equity compensation and tax-related transactions for a senior executive in the biotechnology/pharmaceutical industry. Such grants are common practice to align executive incentives with long-term company performance and shareholder value in this sector.

Stakeholder Impact

• Shareholders: The grant of equity awards to a key executive aligns management's interests with shareholder value creation over the long term. The tax-related sale is a minor, non-discretionary event.
• Employees: The equity compensation structure reflects standard practices for executive incentives.

Next Steps

• Vesting of 25% of Restricted Stock Units on January 2, 2027.
• Vesting of 25% of Stock Options on January 2, 2027, followed by monthly installments.
• Continued service of the Chief Operating Officer to meet vesting conditions.

Key Dates

Keywords

Monte Rosa Therapeutics, GLUE, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Chief Operating Officer, Jennifer Champoux, Tax Withholding